Pre-Surgical “Window of opportunity” trial of the Combination of Metformin and Atorvastatin in Newly Diagnosed Operable Breast Cancer

Protocol: 
AAAM2306
Phase: 
Early Phase I

Pre-Surgical “Window of opportunity” trial of the Combination of Metformin and Atorvastatin in Newly Diagnosed Operable Breast Cancer

The purpose of this study is to determine the effects of combining metformin
and atorvastatin
treatment in patients with newly diagnosed breast cancer during the interval
between breast biopsy and surgery. Metformin is a common treatment for
patients with diabetes, and atorvastatin is a common therapy for elevated
cholesterol. We will examine the effects of the combination of metformin
plus atorvastatin on changes in breast tumor tissue as well as various blood
levels, including insulin and cholesterol levels. The combination of
metformin and atorvastin is an experimental treatment for your condition.

Are you Eligible? (Inclusion Criteria)

To be eligible for this study, patients must:
- be female with confirmed invasive breast cancer
- be age 21 or older
- have no prior chemotherapy, radiation therapy, or breast resection in the
last 6 months

Specialty Area(s)

Trial Location

Herbert Irving Comprehensive Cancer Center
161 Fort Washington Ave.
Herbert Irving Pavilion
New York, NY 10032
United States